Integrated Proteogenomic Characterization of Medullary Thyroid Carcinoma
Xiao Shi,Yaoting Sun,Cenkai Shen,Yan Zhang,Rongliang Shi,Fan Zhang,Tian Liao,Guojun Lv,Zhengcai Zhu,Lianghe Jiao,Peng Li,Tiansheng Xu,Ning Qu,Naisi Huang,Jiaqian Hu,Tingting Zhang,Yanzi Gu,Guangqi Qin,Haixia Guan,Weilin Pu,Yuan Li,Xiang Geng,Tongzhen Chen,Shenglin Huang,Zhikang Zhang,Shuting Ge,Wu Wang,Weibo Xu,Pengcheng Yu,Zhongwu Lu,Yulong Wang,Liang Guo,Yu Wang,Tiannan Guo,Qinghai Ji,Wenjun Wei
DOI: https://doi.org/10.1038/s41421-022-00479-y
IF: 38.079
2022-01-01
Cell Discovery
Abstract:Medullary thyroid carcinoma (MTC) is a rare neuroendocrine malignancy derived from parafollicular cells (C cells) of the thyroid. Here we presented a comprehensive multi-omics landscape of 102 MTCs through whole-exome sequencing, RNA sequencing, DNA methylation array, proteomic and phosphoproteomic profiling. Integrated analyses identified BRAF and NF1 as novel driver genes in addition to the well-characterized RET and RAS proto-oncogenes. Proteome-based stratification of MTCs revealed three molecularly heterogeneous subtypes named as: (1) Metabolic, (2) Basal and (3) Mesenchymal, which are distinct in genetic drivers, epigenetic modification profiles, clinicopathologic factors and clinical outcomes. Furthermore, we explored putative therapeutic targets of each proteomic subtype, and found that two tenascin family members TNC/TNXB might serve as potential prognostic biomarkers for MTC. Collectively, our study expands the knowledge of MTC biology and therapeutic vulnerabilities, which may serve as an important resource for future investigation on this malignancy.